Education
About Us
Working with TipRanks
Follow Us
Beyondspring Inc (BYSI)
NASDAQ:BYSI
BYSI Stock Chart & Stats
$1.66
-$0.09(-5.17%)
At close: 4:00 PM EST
$1.66
-$0.09(-5.17%)
Day’s Range― - ―
52-Week Range$0.98 - $3.44
Previous CloseN/A
Volume3.10K
Average Volume (3M)478.07K
Market Cap
$55.93M
Enterprise Value$43.44M
Total Cash (Recent Filing)$12.62M
Total Debt (Recent Filing)$406.00K
Price to Earnings (P/E)―
Beta0.45
Next Earnings
May 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding41,122,320
10 Day Avg. Volume1,393,566
30 Day Avg. Volume478,066
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)-1.97
Price to Sales (P/S)0.00
P/FCF Ratio-3.89
Enterprise Value/Market Cap0.78
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.07K
Enterprise Value/Ebitda-5.59
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.98
Revenue Forecast (FY)$194.65M
Bulls Say, Bears Say
Bulls Say
Innovative Product PipelineThe development of Plinabulin as a novel cancer therapy positions BeyondSpring for potential breakthroughs in oncology, offering long-term growth opportunities if successful in clinical trials and commercialization.
Strategic PartnershipsBy leveraging partnerships and licensing agreements, BeyondSpring can enhance its market reach and financial stability, potentially securing funding and expertise to advance its drug candidates.
Focus On High Unmet NeedsTargeting high unmet medical needs in cancer treatment can lead to significant market demand and competitive advantage, driving long-term growth if therapies prove effective.
Bears Say
Zero RevenueThe absence of revenue in 2024 indicates severe financial challenges, limiting the company's ability to invest in R&D and sustain operations without external funding.
Negative EquityNegative equity suggests liabilities exceed assets, posing significant financial risk and limiting the company's ability to secure additional financing on favorable terms.
Reliance On External FundingDependence on external funding to sustain operations highlights financial instability and raises concerns about long-term viability without a clear path to profitability.
Beyondspring News
BYSI FAQ
What was Beyondspring Inc’s price range in the past 12 months?
Beyondspring Inc lowest stock price was $0.98 and its highest was $3.44 in the past 12 months.
What is Beyondspring Inc’s market cap?
Beyondspring Inc’s market cap is $55.93M.
When is Beyondspring Inc’s upcoming earnings report date?
Beyondspring Inc’s upcoming earnings report date is May 06, 2026 which is in 66 days.
How were Beyondspring Inc’s earnings last quarter?
Beyondspring Inc released its earnings results on Nov 12, 2025. The company reported -$0.038 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.038.
Is Beyondspring Inc overvalued?
According to Wall Street analysts Beyondspring Inc’s price is currently Overvalued.
Does Beyondspring Inc pay dividends?
Beyondspring Inc does not currently pay dividends.
What is Beyondspring Inc’s EPS estimate?
Beyondspring Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Beyondspring Inc have?
Beyondspring Inc has 41,122,320 shares outstanding.
What happened to Beyondspring Inc’s price movement after its last earnings report?
Beyondspring Inc reported an EPS of -$0.038 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.636%.
Which hedge fund is a major shareholder of Beyondspring Inc?
Currently, no hedge funds are holding shares in BYSI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Beyondspring Stock Smart Score
Company Description
Beyondspring Inc
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.
Technical Analysis
Plus Therapeutics
―
X4 Pharmaceuticals
―
ABVC BioPharma
―
Prelude Therapeutics
―
Gain Therapeutics
―
Ownership Overview
9.80% Insiders
1.52% Mutual Funds
9.34% Other Institutional Investors
77.69% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---